Orient Europharma Co., Ltd. (4120) Stock Price & Analysis
4120 Stock Chart & Stats
- Day’s Range
- TWD 41.10 - TWD 42.45
- 52-Week Range
- TWD 41.10 - TWD 49.60
- Previous Close
- TWD 42.30
- Volume
- N/A
- Average Volume (3M)
- 20.33K
- Market Cap
- TWD 3.67B
- Enterprise Value
- TWD 6.92B
- Total Cash (Recent Filing)
- TWD 1.67B
- Total Debt (Recent Filing)
- TWD 3.53B
- Price to Earnings (P/E)
- ―
- Beta
- 0.14
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 20, 2026
- Dividend Yield
- 9.46%
4120 FAQ
What was Orient Europharma Co., Ltd.’s price range in the past 12 months?
What is Orient Europharma Co., Ltd.’s market cap?
When is Orient Europharma Co., Ltd.’s upcoming earnings report date?
How were Orient Europharma Co., Ltd.’s earnings last quarter?
Is Orient Europharma Co., Ltd. overvalued?
Does Orient Europharma Co., Ltd. pay dividends?
What is Orient Europharma Co., Ltd.’s EPS estimate?
How many shares outstanding does Orient Europharma Co., Ltd. have?
What happened to Orient Europharma Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Orient Europharma Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Orient Europharma Co., Ltd.
Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, such as cardiovascular issues, metabolic disorders, neurological ailments, obstetric and gynecological health, respiratory diseases, andrological concerns, immunological responses, as well as antibiotics and anti-cancer therapies. Beyond prescription drugs, the company offers nutritional and infant care items, including specialized milk formulas and dietary supplements, marketed under the brand names Karihome, Babecare, and Ostricare. Additionally, it supplies health-related supplements, notably Buccotherm-branded thermal water, designed for the management of oral and periodontal conditions. The company's diverse product range extends to skincare, featuring items like essences, creams, lotions, eye creams, facial toners, and skin-repairing treatments available through its AGLab line. It also distributes skincare oils, body lotions, and gels for dry skin under the well-known Bio-Oil brand, and markets children's skincare solutions through the Mister Baby brand. Furthermore, OEP oversees ISISPHARMA, a dermatology laboratory dedicated to the creation and distribution of specialized dermo-cosmetic goods. Orient EuroPharma is actively involved in extensive research and development efforts, with several key compounds in its pipeline. These include Multikine, an immunotherapy treatment for head and neck cancer currently undergoing Phase III clinical trials; NC-6004, a platinum-based micelle chemotherapeutic agent also in Phase III; ASC-J9, a molecular chemical entity targeting androgen receptor degradation, which has successfully finished its Phase IIb clinical study; and 2ccPA, a phospholipid derivative for symptomatic knee osteoarthritis, progressing through Phase I clinical trials. Established in 1982, Orient EuroPharma Co., Ltd. maintains its headquarters in Taipei, Taiwan.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mon-Lin Tsai
- Employees
- 339
- Website
- www.oepgroup.com
- Address
- No. 128, Chengde Road, Taipei, TP, 112052, TW
Orient Europharma Co., Ltd. (4120) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |
